BRAF-mutant Non-Small Cell Lung Cancer (BRAF + NSCLC) - Pipeline Insight, 2024

This “BRAF-mutant Non-Small Cell Lung Cancer - Pipeline Insight, 2024” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in BRAF-mutant Non-Small Cell Lung Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

BRAF-mutant Non-Small Cell Lung Cancer: Understanding

BRAF-mutant Non-Small Cell Lung Cancer: Overview

About 80% to 85% of lung cancers are Non-Small Cell Lung Cancer. The main subtypes of Non-Small Cell Lung Cancer are adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. These subtypes, which start from different types of lung cells are grouped together as Non-Small Cell Lung Cancer because their treatment and prognoses (outlook) are often similar.

BRAF mutated lung cancer is a rare form of NSCLC. BRAF mutations have been reported in about 4% of non-small cell lung cancers (NSCLC). They are most common in adenocarcinoma non-small cell lung cancer. BRAF V600E mutations specifically occur in about 1-2% of non-small cell lung cancer patients. Most patients with BRAF V600E tend to have a smoking history.

BRAF is the name of both a gene and a protein. The BRAF protein helps control cell growth. When there is a mutation in the BRAF gene, it creates an abnormal protein that sends signals that lead to uncontrolled cell growth and cancer. The BRAF protein works with another protein called MEK to regulate the growth of cells. There are different mutations within BRAF, but the one with FDA-approved treatment in lung cancer is BRAF V600E. This mutation is a specific variation in the BRAF protein. In cells with this mutation, BRAF can always turn on the MEK protein.

Identification of BRAF Mutations
BRAF mutations can be found in several ways. The pathologist can use a test to look specifically for BRAF mutations in the tumor. However, most physicians prefer a testing approach that can look for mutations in multiple genes at one time using a single biopsy. This is called comprehensive next-generation sequencing (NGS). This type of testing places tissue from a patient’s tumor (gathered from a biopsy) in a machine that looks for a large number of possible biomarkers at one time. There may be some situations where a patient can’t undergo the biopsy needed to perform NGS, and so liquid biopsy is recommended. A liquid biopsy can look for certain biomarkers in a patient’s blood.

Treatment and Management
First-line treatment for BRAF V600E mutations in lung cancer is either: a combination of the targeted therapies dabrafenib and trametinib (pills that target the mutation) or immunotherapy with or without chemotherapy
The targeted therapy drug combination helps address the BRAF mutation (dabrafenib) and the MEK protein (trametinib). Patients with a different type of BRAF mutation should ask their doctor about a clinical trial. The standard of care for patients with a different BRAF mutation is immunotherapy with or without chemotherapy.

BRAF-mutant Non-Small Cell Lung Cancer- Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the BRAF-mutant Non-Small Cell Lung Cancer pipeline landscape is provided which includes the disease overview and BRAF-mutant Non-Small Cell Lung Cancer treatment guidelines. The assessment part of the report embraces, in depth BRAF-mutant Non-Small Cell Lung Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, BRAF-mutant Non-Small Cell Lung Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence BRAF-mutant Non-Small Cell Lung Cancer R&D. The therapies under development are focused on novel approaches to treat/improve BRAF-mutant Non-Small Cell Lung Cancer.

BRAF-mutant Non-Small Cell Lung Cancer Emerging Drugs Chapters

This segment of the BRAF-mutant Non-Small Cell Lung Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

BRAF-mutant Non-Small Cell Lung Cancer Emerging Drugs

Encorafenib/Binimetinib: Pierre Fabre Medicament
BRAFTOVI (encorafenib) is a BRAF kinase inhibitor, indicated in combination with MEKTOVI (binimetinib) for the treatment of adult patients with unresectable or metastatic melanoma with a BRAFV600 mutation. The combination is currently investigated in Metastatic BRAFV600-mutant Non-Small Cell Lung Cancer in Phase II trial with completion expected in March 2025. This combination is indicated and being tested for several other indications.

XP-102: Xynomic Pharmaceuticals, Inc.

XP-102 is a second generation potent and selective pan-RAF inhibitor uniquely binding to the DFG-out conformation, whereas marketed BRAF inhibitors occupy the DFG-in conformation. XP-102 holds potential as an innovative therapy against B-RAF V600 mutated solid tumors including CRC and non-small cell lung cancer and hairy cell leukemia. The drug is currently being investigated for several tumor including non-small cell lung cancer in Phase I/II which is expected to be completed by December 2024.

BRAF-mutant Non-Small Cell Lung Cancer: Therapeutic Assessment

This segment of the report provides insights about the different BRAF-mutant Non-Small Cell Lung Cancer drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in BRAF-mutant Non-Small Cell Lung Cancer

There are approx. 10+ key companies which are developing the therapies for BRAF-mutant Non-Small Cell Lung Cancer. The companies which have their BRAF-mutant Non-Small Cell Lung Cancer drug candidates in the most advanced stage, i.e. Phase II include, Pierre Fabre Medicament’s drug.

Phases

This report covers around 10+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

BRAF-mutant Non-Small Cell Lung Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

BRAF-mutant Non-Small Cell Lung Cancer: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses BRAF-mutant Non-Small Cell Lung Cancer therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging BRAF-mutant Non-Small Cell Lung Cancer drugs.

BRAF-mutant Non-Small Cell Lung Cancer Report Insights

• BRAF-mutant Non-Small Cell Lung Cancer Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

BRAF-mutant Non-Small Cell Lung Cancer Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing BRAF-mutant Non-Small Cell Lung Cancer drugs?
• How many BRAF-mutant Non-Small Cell Lung Cancer drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of BRAF-mutant Non-Small Cell Lung Cancer?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the BRAF-mutant Non-Small Cell Lung Cancer therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for BRAF-mutant Non-Small Cell Lung Cancer and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Pierre Fabre Medicament
• Xynomic Pharmaceuticals, Inc.
• Kinnate Biopharma
• Revolution Medicines, Inc.
• Black Diamond Therapeutics, Inc.

Key Products

• Encorafenib/Binimetinib
• XP-102
• KIN-2787
• RMC-4630
• BDTX-4933

This product will be delivered within 1-3 business days.